130 pipeline articles
SABR shows worse survival in ultracentral pulmonary oligometastases compared to nonultracentral tumors
Tumor location matters: ultracentral spots linked to worse survival in lung metastasis patients
This secondary analysis of the SABR-5 Phase 2 trial evaluated progression-free and overall survival in 41 patients with ultracentral pulmona…
Tumor location matters. Patients with ultracentral lung metastases had shorter survival times than those with nonultracentral spots after ra…
SABR in oligometastatic cancer showed median overall survival of 64.6 months in a single-arm phase 2 study.
SABR offers five-year survival hope for patients with limited cancer spread
This single-arm phase 2 trial evaluated stereotactic ablative radiotherapy (SABR) in 380 patients with oligometastatic cancer across six Can…
Patients with few cancer spots lived longer with SABR treatment. Five-year survival reached 58.6 percent in this Canadian study.
Tislelizumab plus chemotherapy and radiotherapy yields 89.1% 3-year disease-free survival in pMMR/MSS locally advanced rectal cancer
Early trial shows high survival rates for rectal cancer patients treated with tislelizumab
This Phase 2 clinical trial evaluated neoadjuvant tislelizumab, chemotherapy, and long-course radiotherapy in 50 patients with pMMR/MSS loca…
A Phase 2 trial found that adding tislelizumab to standard care helped 89% of patients stay free of cancer for three years. This approach wo…
MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
Early MRI scans shrink after treatment to help spot prostate cancer recurrence sooner
This prospective phase II trial protocol reports early results from 97 men with unfavorable-intermediate-risk or high-risk localized prostat…
New MRI scans taken before and during treatment for prostate cancer show clear shrinkage that could help doctors target the tumor more accur…
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns
Treatment for severe anemia reveals two paths to cancer risk
This phase 2 observational study followed 204 patients with severe aplastic anemia treated with immunosuppression plus eltrombopag for a med…
New research tracks cancer risks in severe anemia patients treated with standard therapy over five years
Burosumab improves phosphate levels in 12 children and adults with fibrous dysplasia over 48 weeks.
Burosumab Restores Phosphate Balance in Rare Bone Disease
This Phase 2 trial enrolled 12 participants (7 children, 5 adults) with fibrous dysplasia to assess burosumab. At 48 weeks, 100% achieved ph…
A drug already used for rare phosphate disorders may finally offer real relief for people with fibrous dysplasia, a painful bone condition t…
Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients.
New Drug Shrinks Stubborn Lymphoma Tumors After Other Treatments Fail
This single-arm, multi-center phase 2 study evaluated abexinostat in 90 patients with relapsed or refractory follicular lymphoma who had rec…
A new treatment is helping some patients with stubborn lymphoma shrink tumors and stay in control for over a year, even after other therapie…
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
EMS Bundle for Pediatric Life-Threatening Asthma Evaluated in PECARN Pilot
Early Meds Could Cut Hospital Stays for Wheezing Kids
This Phase 2 pilot trial in the Pediatric Emergency Care Applied Research Network assessed an EMS treatment bundle and checklist for childre…
Kids with severe asthma might avoid hospital stays if they get breathing meds right after the 911 call.
Spanish RSBQ Validation in 51 Latin American Rett Syndrome Caregivers
New Spanish Tool for Rett Syndrome Improves Care for Thousands
This observational linguistic validation study assessed a Spanish translation of the Rett Syndrome Behaviour Questionnaire among 51 Spanish-…
A Spanish-language behavior checklist for Rett Syndrome now matches the English version, helping Spanish-speaking families get more accurate…
Eltrombopag monotherapy assessed in moderate aplastic anemia and unilineage bone marrow failure disorders.
Oral Drug May Reduce Need for Frequent Blood Transfusions
This Phase 2 trial evaluated eltrombopag by mouth once a day in 34 people at least 2 years of age with moderate aplastic anemia or unilineag…
A new oral medication offers hope for patients who rely on regular blood transfusions.
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients.
New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Vosoritide daily injections in prepubertal hypochondroplasia patients over 12 months
Vosoritide Changes Growth Hormone Signals
This phase 2, single-arm, unblinded trial evaluated daily vosoritide 15 μg/kg in prepubertal patients aged 3 to 11 years with hypochondropla…
This new research shows how a specific growth medicine works inside the body to help short children grow taller.
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression.
New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Neoadjuvant atezolizumab shows spatial biomarker changes in operable urothelial carcinoma patients.
How a Bladder Cancer Drug Remodels the Tumor Neighborhood
This single-arm, phase II trial evaluated neoadjuvant atezolizumab in patients with operable urothelial carcinoma. Results indicated that ce…
A bladder cancer drug physically breaks down the walls blocking immune cells in tumors, helping doctors predict which patients will respond …
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients.
New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Extensive intraoperative peritoneal lavage after gastrectomy for gastric cancer with peritoneal cytology positivity.
Can washing the belly during surgery help prevent stomach cancer from coming back?
This single-arm exploratory phase 2 trial in 13 patients with gastric cancer and positive peritoneal cytology evaluated extensive intraopera…
A thorough belly wash during stomach cancer surgery kept patients free from recurrence for 14.5 months if their fluid tests showed no cancer…
MRIRA annotation scheme shows high agreement for medication safety incident reports in NHS
Can computers reliably read your hospital safety reports about medication errors?
A methodological study developed and evaluated the Medication-Related Incident Report Annotation (MRIRA) scheme using 55 and 30 healthcare i…
Computers can read hospital safety reports about medication errors with 85% to 91% accuracy, though they struggle with complex details.
Phase 1b trial of intravenous B001 shows favorable safety in aquaporin-4-positive NMOSD patients.
A New MS-Like Disease Drug Passes Its First Human Safety Test
This Phase 1b randomized, double-blind, placebo-controlled trial evaluated intravenous B001 in 22 patients with aquaporin-4 immunoglobulin G…
A new drug for a rare nerve disease that can cause blindness and paralysis passed its first human safety test with no severe side effects se…
Phase Ia trial of RH5.1 protein with Matrix-M adjuvant in malaria-naive UK adults showed safety and similar immunogenicity across two booster regimens.
A Malaria Vaccine Candidate Holds Strong — Even With a Smaller Booster Dose
This Phase Ia clinical trial evaluated the safety and immunogenicity of RH5.1 soluble protein with Matrix-M adjuvant in malaria-naive UK adu…
A malaria vaccine candidate produced strong immune responses even when the final booster dose was cut in half, potentially helping extend va…
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease.
Study looks at two antibody drugs for high-risk multiple myeloma
This phase 2 single-arm study evaluated a talquetamab and teclistamab combination in a high-risk population with relapsed/refractory multipl…
A new drug combo for high-risk multiple myeloma helped 79% of patients respond, but 31% faced serious infections and five treatment-related …
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer
New Drug Combo Helps Breast Cancer After CDK4/6 Failure
This phase 2 trial evaluated tucidinostat plus metronomic capecitabine with endocrine therapy in 66 patients with HR-positive HER2-negative …
A new drug mix shrinks tumors in advanced breast cancer patients whose disease grew after standard treatments failed.
Phase 2 trial tests single-dose IV iron isomaltoside in severe aortic stenosis with iron deficiency
Early study suggests iron treatment may help heart function in severe aortic stenosis patients.
This Phase 2, double-blind, randomized, placebo-controlled trial tested a single intravenous dose of iron isomaltoside versus placebo in pat…
Treating iron deficiency may improve exercise capacity and reduce fatigue in people with severe aortic stenosis, according to early trial re…
Pilot study of fluoxetine and calcium in musculoskeletal trauma victims showed no measurable benefit.
A Common Antidepressant May Ease Recovery After Serious Injuries
This pragmatic pilot study evaluated fluoxetine and calcium in 68 victims of musculoskeletal trauma. Follow-up occurred at 41.6 months, but …
A common low-dose antidepressant may help adults recover emotionally after serious bone and joint injuries, addressing the hidden mental tol…
Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
For patients with advanced head and neck cancer, a new drug showed a 21% response rate in early testing.
This multicenter, Phase IIa trial evaluated intravenous becotatug vedotin in 67 patients with recurrent or metastatic squamous cell carcinom…
A new drug shrank tumors in 21% of patients with advanced head and neck cancer who had run out of standard treatment options.
Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer.
New Drug Combo Helps Older Pancreatic Cancer Patients Live Longer
This Phase II multicentric study evaluated adapted-dose FOLFIRINOX in 72 elderly patients (aged 70 years or older) with metastatic pancreati…
A new drug mix helps older pancreatic cancer patients live longer while keeping them active, provided doctors check specific genes first to …
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
Hope for Bladder Cancer When Chemo Isn't an Option
This Phase II trial evaluated neoadjuvant nivolumab alone or with ipilimumab in 30 cisplatin-ineligible patients with muscle-invasive bladde…
Patients with advanced bladder cancer who can't take standard chemo may now qualify for surgery after a new immunotherapy treatment.
SABR shows 46% 5-year overall survival in unfit NSCLC patients in phase 2 trial
Precision Radiation Offers a Real Option for Lung Cancer Patients Who Can't Do Chemo
A non-randomized phase 2 trial of 50 patients with unresectable locally advanced NSCLC unfit for concurrent chemoradiation found 5-year over…
Nearly half of patients treated with precision radiation were still alive at five years, offering hope for lung cancer patients too frail fo…
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial.
Some Liver Cancer Patients Are Surviving Far Longer on a New Drug Combination
This Phase IIa trial evaluated regorafenib plus nivolumab as an add-on therapy in patients with hepatocellular carcinoma who had progressed …
A combination of regorafenib and nivolumab showed unexpectedly long survival in people with advanced liver cancer who had already exhausted …
![In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer.](https://images.unsplash.com/photo-1766297247924-6638d54e7c89?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3w5MDg5NDR8MHwxfHNlYXJjaHw5fHxtZWRpY2FsJTIwcmVzZWFyY2glMjBzY2llbmNlfGVufDF8MHx8fDE3NzU4ODUyMzd8MA&ixlib=rb-4.1.0&q=80&w=1080)
In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer.
A New Scan That Lights Up Hidden Lung Cancer Spread
This prospective, phase 2, cross-sectional imaging trial evaluated [Ga]Ga-SSO120 PET/CT versus CT in 19 patients with small cell lung cancer…
A new kind of PET scan found hidden tumors in patients with aggressive lung cancer, including bone and brain spread that standard imaging mi…
Stereotactic body radiotherapy for painful spinal metastases showed high pain response rates in a single-arm phase II study.
Second Radiation Stops Spinal Pain Fast
This single-centre, single-arm phase II study evaluated re-irradiation stereotactic body radiotherapy (SBRT) in 34 patients with painful spi…
A second round of precise radiation safely stops severe spinal pain in most patients, offering new hope for those who previously had no opti…
Ibrutinib monotherapy showed durable progression-free survival in patients with TP53 aberrations or advanced age.
Ten Years on One Pill: What Long-Term Ibrutinib Revealed
This investigator-sponsored phase 2 study evaluated single-agent ibrutinib in 84 patients with chronic lymphocytic leukemia (CLL) harboring …
A decade of follow-up shows a daily pill can give high-risk leukemia patients years of control, but staying on it is not easy.
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms.
Why Some BRCA Breast Cancers Shrug Off Talazoparib Before Surgery
This Phase II neoadjuvant trial evaluated talazoparib in patients with germline mutant breast tumors. Mechanistic analysis showed that BRN2 …
Some BRCA breast cancers shrink under talazoparib, but others find hidden escape routes that let them ignore the drug before surgery.
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
A New Drug Shows Promise for Tough-to-Treat Nasopharyngeal Cancer
A phase IIa single-arm trial of 61 patients with platinum-refractory recurrent or metastatic nasopharyngeal carcinoma found an objective res…
For patients with a hard-to-treat head and neck cancer who have few treatments left, a new experimental therapy is showing encouraging resul…
First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases.
Untreated Brain Metastases Respond Well to Osimertinib
This single-arm phase II trial evaluated first-line osimertinib in 100 patients with EGFR-mutated non-small cell lung cancer, including thos…
Osimertinib, a lung cancer drug, effectively treats untreated brain metastases, with an 81.8% response rate for measurable brain spots in a …
Phase 2 trial of JNJ-73763989-based regimen shows no HBsAg seroclearance at primary endpoint in HBeAg-positive CHB
New combo lowers hepatitis B virus levels
A phase 2 trial in 54 treatment-naïve, HBeAg-positive chronic hepatitis B patients tested a regimen of JNJ-73763989 ± bersacapavir with nucl…
A new drug combination successfully lowered virus levels in many patients, though clearing the virus completely happened in only about one o…
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients.
Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Trifluridine/tipiracil plus irinotecan and bevacizumab in metastatic colorectal cancer resistant to prior chemotherapy
A New Second-Line Combo Shows Promise for Advanced Colon Cancer
This multicenter, single-arm, phase II trial evaluated biweekly trifluridine/tipiracil, irinotecan, and bevacizumab in 60 patients with meta…
For patients whose advanced colon cancer has stopped responding to initial chemo, a new drug combination is showing it can effectively fight…
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients.
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients.
A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide.
Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility study
Blood Tests Replace Biopsies for Prostate Cancer
A phase 2 neoadjuvant trial in 22 patients with high-risk localized prostate cancer found liquid-based genomic profiling achieved 100% seque…
A simple blood draw now replaces painful prostate biopsies, capturing the same genetic details doctors need to pick the best treatment.
Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer
Can new drugs help advanced thyroid cancer patients keep their daily life stable?
An uncontrolled phase 2 trial of 22 patients with BRAF V600E-mutated thyroid cancer found encorafenib plus binimetinib was associated with g…
A new drug combination helped advanced thyroid cancer patients maintain daily life stability without worsening their quality of life during …
Simulation study suggests BF-BOLD reduces overdose rates and enhances safety in Phase I trials compared to conventional designs.
Can a smarter trial design make early cancer drug tests safer and more sustainable?
This Phase I simulation study compared the Backfill Bayesian Ordered Lattice Design (BF-BOLD) against conventional Phase I trial designs. Th…
A smarter trial design reduces overdose rates and improves safety while preserving drug effectiveness during early cancer tests.
Ponatinib in CP-CML resistant to prior TKI or T315I mutation showed molecular response at Month 12
Ponatinib doses show early signs in resistant chronic myeloid leukemia patients
This Phase 2 study evaluated ponatinib in 283 participants with chronic-phase chronic myeloid leukemia (CP-CML) resistant to prior tyrosine-…
Ponatinib at three daily doses showed early signs of helping resistant chronic myeloid leukemia patients reach a key molecular response goal…
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04.
Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Chinese rehabilitation students show low knowledge of physical activity guidelines; learning linked to practice
Do future physical therapists learn how to prescribe exercise? Many don't.
A mixed-methods study of 105 Chinese rehabilitation students and 10 therapists found 66.7% of students reported not being taught WHO physica…
Two-thirds of Chinese physical therapy students were never taught how much exercise is healthy, leaving many future therapists unprepared to…
Phase II trial shows high remission and survival with frontline ATRA-ATO for newly diagnosed APL
Can a chemotherapy-free treatment beat a rare, aggressive leukemia?
A prospective multicenter phase II trial in 81 newly diagnosed APL patients in Japan found that frontline ATRA-ATO therapy achieved a 95.1% …
A chemotherapy-free treatment for acute promyelocytic leukemia achieved 95% remission and 95% survival three years later in a Japanese trial…
Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia Areata.
Centralized hair loss scoring showed better consistency than local ratings in mild Alopecia Areata trials
This Phase 2 clinical trial compared centralized measurement of hair loss via standardized photographic images against local SALT score rati…
Centralized hair loss scoring cut measurement errors by half compared to local ratings in mild Alopecia Areata trials, boosting trial succes…
Regional motif diversity score in cfDNA predicts pembrolizumab response in head and neck cancer
Can a DNA pattern predict who will heal from head and neck cancer immunotherapy?
A phase II trial in 68 patients with locally advanced, resectable HNSCC found that a regional motif diversity score (rMDS) in cell-free DNA …
A new DNA pattern in blood can reliably predict which head and neck cancer patients will respond to immunotherapy and live longer without th…
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer.
Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.
Hypofractionated stereotactic radiation therapy showed high local control in breast cancer brain metastases.
FSRT shows promising results for brain metastases in breast cancer patients
This prospective single-arm phase 2 trial evaluated fractionated stereotactic radiation therapy (FSRT) in 173 patients with breast cancer an…
Fractionated stereotactic radiation therapy kept brain cancer controlled in 88.6% of breast cancer patients after one year with no severe si…
In Silico Modeling Predicts Fezolinetant Hepatotoxicity Risk in MAFLD Population
Could a menopause drug harm the liver? A computer model offers clues.
Quantitative systems toxicology modeling simulated fezolinetant hepatotoxicity in virtual populations. The model predicted no ALT elevations…
A computer model predicts a menopause drug might cause rare liver injury in people with fatty liver disease, but higher doses could be safer…
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…
Phase 2a trial of dazodalibep plus belatacept shows 25% acute rejection rate in kidney transplant patients
Early study tests two-drug combination to prevent kidney transplant rejection
A phase 2a, open-label, single-arm trial in 23 adults undergoing first kidney transplants evaluated dazodalibep plus belatacept as sole main…
A new two-drug kidney treatment was safe but failed to prevent rejection in most patients during this early study.
Phase 2 trial of muscadine grape extract added to ADT for recurrent prostate cancer fatigue
Muscadine grape extract studied for fatigue in men with recurrent prostate cancer
A Phase 2 randomized controlled trial enrolled 106 men with recurrent prostate cancer on androgen deprivation therapy to test muscadine grap…
Men with recurrent prostate cancer taking hormone therapy may feel less extreme fatigue when adding a natural muscadine grape extract supple…
Phase 2 trial assesses JYNNEOS vaccine in adolescents for monkeypox prevention
Is the monkeypox vaccine safe and effective for teenagers?
A Phase 2 open-label, non-placebo controlled trial evaluated the standard subcutaneous JYNNEOS regimen in 315 vaccinia-naïve adolescents (12…
A new study is looking at whether the standard monkeypox vaccine works for adolescents. Researchers compared immune responses and side effec…
Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer
Can a single radiation dose protect women after breast cancer surgery?
A prospective single-institution phase 2 trial of 148 patients with early-stage breast cancer after breast-conserving surgery found single-f…
A single radiation dose for breast cancer recovery showed low recurrence and mild side effects in early results from a new treatment approac…
Qualitative study finds knowledge gaps and insurance concerns about prostate cancer genetic testing
What stops men from getting genetic testing for prostate cancer?
A qualitative and survey study of 20 men with prostate cancer, plus patients, carers, and healthcare providers, found generally low knowledg…
Fear of insurance discrimination and low knowledge about genetic testing are stopping many men from getting prostate cancer tests that could…
Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
Drug combination shows promise for bladder cancer patients who cannot take standard chemotherapy
A single-arm phase 2 study of 49 patients with muscle-invasive bladder cancer ineligible for cisplatin found a clinical complete response ra…
A new drug combination helped 39% of bladder cancer patients who couldn't take standard chemotherapy achieve a complete response before surg…
Phase 2 trial proposes 129XeMRI and RNA sequencing to study airway remodeling in obese asthma
Can a new type of lung scan reveal why asthma hits obese people harder?
A Phase 2 clinical trial proposal aims to use hyperpolarized 129XeMRI and single-cell RNA sequencing to investigate mechanisms of regional a…
A new lung scan maps hidden scarring in obese asthma patients, helping explain why these breathing problems are harder to treat than in othe…
Phase 2 trial protocol tests oral hydrocortisone for PTSD prevention after trauma
Study tests single hydrocortisone pill after trauma to prevent PTSD symptoms
A phase 2 randomized controlled trial protocol describes a study of 201 trauma survivors in emergency departments. Participants receive a si…
A single hydrocortisone pill taken within six hours of trauma might help the brain process memories differently to prevent PTSD symptoms in …
Radiomics models predict progression in lung oligometastases after SABR in phase II trial
Radiomics models show promise for predicting outcomes after lung metastasis radiation
A single-arm phase II trial of 126 patients with lung oligometastases developed radiomics models to predict progression-free survival and ea…
Computer analysis of medical scans can better predict when lung cancer will spread after radiation treatment than standard clinical informat…
Phase 2 trial of ketamine for tinnitus in 42 adults did not report main results
Can a single ketamine dose quiet the brain's noise in people with tinnitus?
A phase 2 clinical trial investigated ketamine hydrochloride versus placebo in 42 adults with tinnitus. The primary outcome was GABA and Glx…
A single ketamine dose may quiet brain noise in tinnitus by blocking glutamate receptors and boosting calming GABA chemicals, offering hope …
Phase 2 trial of Paxlovid for Long COVID cognitive, autonomic, and exercise symptoms completed.
Can Paxlovid help people with Long COVID? A major trial is underway.
A prospective, multi-center, double-blind, randomized, controlled Phase 2 trial enrolled 964 individuals with PASC to evaluate Paxlovid. The…
A major trial is testing whether Paxlovid can ease Long COVID symptoms like brain fog and severe fatigue in nearly 1,000 people.
Cryoablation shows 3.64% 5-year recurrence in selected early-stage breast cancer patients
Cryoablation shows low recurrence rate in early-stage breast cancer after six years
A prospective phase 2 multicenter study of 83 women aged ≥50 with stage I, HR+, HER2-, node-negative invasive ductal carcinoma found a 5-yea…
Cryoablation kept early-stage breast cancer from returning in 97.6% of women over six years, with no serious side effects reported in this s…
ENGAGE program shows feasibility and preliminary signal for participation after chronic stroke in pilot trial
Can a peer-led program help stroke survivors reconnect with their communities?
A phase 2a single-arm pilot trial of 30 community-dwelling stroke survivors assessed a 6-week ENGAGE intervention co-facilitated by peer men…
A new stroke support program helped 30 survivors reconnect with their communities, showing high satisfaction and safe participation in socia…
Phase 2 trial compares lidocaine/estradiol cream, nortriptyline, and combination for vestibulodynia subtypes
Can a cream or pill help women with chronic pelvic pain?
A 52-month, phase 2, randomized, double-blinded, placebo-controlled trial in 209 women with distinct vestibulodynia subtypes compared 5% lid…
Women with chronic pelvic pain may finally find relief as a new trial compares creams, pills, and combined treatments to personalize care fo…
Phase II trial opens for Viscum album extract adjuvant therapy in relapsed osteosarcoma
Early study explores mistletoe extract as additional treatment for relapsed bone cancer in young people
A Phase II trial is now open to evaluate adjuvant Viscum album extract (Iscador® P) in children and AYAs with relapsed, resectable osteosarc…
A pilot study found that adding mistletoe extract after surgery helped 55% of young people with relapsed bone cancer stay alive without dise…
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab
Does tumor size predict how well immunotherapy works for rare cancers?
A secondary analysis of a phase 2 basket trial in 722 patients with rare/ultrarare malignancies found that larger baseline tumor burden was …
For rare cancers treated with immunotherapy, larger tumors at the start were linked to shorter overall survival, but not to how long patient…
Phase 2 trial links early monocyte elevation to response in gastric cancer immunotherapy
Small study finds immune cell changes linked to better response in gastric cancer treatment
A phase 2 trial in 24 patients with metastatic gastric cancer receiving first-line pembrolizumab plus XELOX found that early elevation of ci…
Patients with metastatic gastric cancer who saw early immune cell changes in their blood were more likely to survive longer while receiving …
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
Phase 2 trial of oral ifetroban in DMD cardiomyopathy reports no safety results yet
Can a new pill help protect the hearts of boys with Duchenne muscular dystrophy?
A phase 2 randomized, double-blind, placebo-controlled trial evaluated low- and high-dose oral ifetroban in 46 males with DMD-associated car…
A new pill called ifetroban is being tested to safely treat heart weakness in boys with Duchenne muscular dystrophy, addressing a leading ca…
Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
Can a targeted radiation treatment help men with advanced prostate cancer?
A prospective, single-arm phase II study of 48 PSMA-avid mCRPC patients treated with 177Lu-PSMA-617 found a 50% PSA response rate and median…
A targeted radiation therapy helped half of men with advanced prostate cancer lower their cancer markers and kept nearly 88% alive after one…
Phase 2 trial of high-dose thoracic reirradiation shows 30-month median OS for recurrent lung cancer
Can high-dose radiation help when lung cancer returns near where it was treated before?
A phase 2 single-arm trial of 60 patients with recurrent lung cancer in the thorax found that high-dose reirradiation (≥45 Gy EQD) achieved …
When lung cancer returns near a previous radiation site, a precise high-dose treatment helped patients survive a median of 30 months with no…
Phase 2 trial tests pre-hospital glucocorticoid pulse in STEMI patients undergoing primary PCI
Phase 2 trial tests steroid pulse for heart attack patients before hospital arrival
A phase 2 randomized controlled trial enrolled 530 STEMI patients treated with primary PCI to test single-dose glucocorticoid pulse therapy …
A new trial tested giving a single steroid dose in ambulances before heart attack patients reach the hospital to reduce permanent heart dama…
Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up
Can a maintenance drug help keep advanced endometrial cancer at bay?
A phase II randomized controlled trial evaluated rucaparib maintenance versus placebo in 79 patients with metastatic/recurrent endometrial c…
A trial testing rucaparib as maintenance therapy for advanced endometrial cancer has finished, but results on whether it delays cancer growt…
Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
Phase 2 trial tests DS-1062a drug for advanced lung cancer with specific genetic changes
A Phase 2 interventional trial evaluated DS-1062a (6.0 mg/kg) in 137 participants with advanced/metastatic NSCLC with actionable genomic alt…
A completed Phase 2 trial tested DS-1062a for advanced lung cancer in 137 people who had already received prior chemotherapy and targeted th…
Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML
Can a new radiation technique make stem cell transplants safer for leukemia?
A phase I/II trial record describes a study of intensity-modulated radiation therapy with etoposide and cyclophosphamide followed by allogen…
Doctors are testing a precise radiation technique to protect healthy organs while preparing patients for life-saving stem cell transplants.
Phase 2 trial explores idelalisib plus ofatumumab in untreated CLL/SLL requiring treatment
Can two drugs together help people with untreated blood cancer?
A phase 2 interventional trial evaluated idelalisib plus ofatumumab in 27 previously untreated CLL/SLL patients requiring therapy. The prima…
For people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment, researchers tested a combinat…
Phase 2 trial tests amlitelimab add-on therapy in adults with moderate-to-severe asthma
Phase 2 trial tests new asthma drug amlitelimab in adults with moderate-to-severe asthma
A phase 2 randomized controlled trial enrolled 437 adults with moderate-to-severe asthma globally to evaluate amlitelimab versus placebo. No…
A new asthma drug called amlitelimab is being tested to see if adding it to current treatments can reduce severe asthma attacks in adults wi…
Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma
Can a patient's own immune cells be turned into a treatment for advanced melanoma?
A prospective, multicenter, phase 2 interventional study evaluated lifileucel (autologous tumor-infiltrating lymphocytes, LN-144) infusion a…
A new treatment uses a patient's own immune cells to fight advanced melanoma, but results from the mid-stage trial are not yet available.
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
Can an oral drug help people with fatty liver disease? Early safety study begins.
A randomized, double-blinded, placebo-controlled, single-center phase 1/2a study enrolled 53 adults with NASH and stage 1-3 fibrosis to asse…
A new oral drug for fatty liver disease has finished its early safety study, with results expected soon to show if it helps stop scarring.
Phase 2 trial tests three Vitamin E doses versus placebo in 200 adults with NAFLD
Vitamin E dosing study in 200 adults with fatty liver disease completes trial
A phase 2 randomized controlled trial enrolled 200 adults with NAFLD to compare three doses of Vitamin E (200 IU, 400 IU, 800 IU) with place…
A completed trial on Vitamin E for fatty liver disease has finished, but the results showing if the doses helped or caused harm are not yet …
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
Could a targeted pill help Chinese patients with a specific lung cancer mutation?
An open-label, multicenter phase II study evaluated capmatinib in 36 Chinese adult patients with advanced NSCLC harboring MET exon 14 skippi…
A targeted pill shrank tumors in Chinese lung cancer patients with a specific MET gene mutation, offering a new treatment option for this ge…
CFZ533 vs Tacrolimus in Kidney Transplant: Phase 2 Study Terminated After Interim Analysis
Did a new drug for kidney transplant patients work better than standard treatment?
A Phase 2 study comparing the anti-CD40 monoclonal antibody CFZ533 to tacrolimus for preventing organ rejection in kidney transplant recipie…
A planned five-year kidney transplant drug trial ended early after an interim look, leaving the key question about the new treatment's perfo…
Letrozole reduces Ki67 in postmenopausal ER+/HER2- breast cancer after 7-30 days pre-surgery
Can a short course of letrozole before surgery help shrink hormone-sensitive breast cancer?
A phase 2 trial of 61 postmenopausal women with ER+/HER2- operable breast cancer evaluated a 7- to 30-day preoperative course of letrozole 2…
Doctors can now get a real-time snapshot of how hormone-sensitive breast cancer responds to letrozole before surgery in postmenopausal women…
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN
Can a gentler, three-part treatment plan reduce side effects for head and neck cancer?
A single-arm phase II trial enrolled 40 previously untreated patients with SCCHN amenable to transoral surgery. Treatment involved 6 weeks o…
A three-part treatment plan for head and neck cancer aims to reduce harsh side effects by tailoring care based on surgery results.
Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI
Can a single blood thinner prevent heart attacks after stent placement?
A single-center, single-arm, prospective phase II pilot study of 200 patients assessed the initial safety of ticagrelor monotherapy after co…
A new pilot study tests if one blood thinner alone can safely prevent heart attacks and stent clots after stent placement for heart attack p…
Phase 2a trial of DFV890 and MAS825 for inflammation in CHD/CHIP patients completes with 31 participants
Can two experimental drugs calm the dangerous inflammation linked to heart disease and a blood condition called CHIP?
A Phase 2a, multi-center, randomized, placebo-controlled, blinded study evaluated the efficacy, safety, and tolerability of DFV890 (oral dai…
A new trial tested two experimental drugs to safely turn down the dangerous inflammation driving heart disease in patients with CHIP.
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise.
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…
Phase 2 trial of BRIMOCHOL, BRIMOCHOL F, and carbachol for presbyopia completes with 18 subjects
Could new eye drops help you read without reading glasses?
A Phase 2, randomized, double-masked, crossover study evaluated BRIMOCHOL, BRIMOCHOL F, and carbachol monotherapy in 18 subjects with emmetr…
New eye drops aim to let people read menus and texts clearly without losing distance vision, offering a potential fix for age-related blurry…
Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
Can immunotherapy before lung cancer surgery help the immune system fight the tumor?
A multi-institutional phase 2 trial has completed enrollment of 35 patients to study neoadjuvant and adjuvant pembrolizumab in stage IB, II,…
Doctors tested giving immunotherapy before lung cancer surgery to see if it safely boosts the immune system's ability to fight the tumor.
MT-2301 Hib vaccine candidate shows efficacy in phase 2 study of 154 infants
How well does a new Hib vaccine protect infants when given with other routine shots?
A phase 2 study evaluated the efficacy and safety of MT-2301 (Haemophilus b conjugate vaccine) co-administered with DPT-IPV in healthy infan…
A new Hib vaccine given with routine shots reached the same antibody protection levels as the current approved vaccine in healthy infants.
Sentinel lymph node technique assessed in multifocal breast cancer (n=216)
Can doctors find the first lymph node cancer might reach in women with multiple breast tumors?
A phase 2 trial assessed the sentinel lymph node technique in 216 patients with multifocal breast cancer. The technique involved subareolar …
Doctors successfully mapped the first lymph node cancer reaches in women with multiple breast tumors using a safe dye and tracer injection t…
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML
Can adding quizartinib to standard chemo help adults with a common type of acute myeloid leukemia?
A randomized phase II trial compared standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in 273 adults with new…
Adding quizartinib to standard chemotherapy for newly diagnosed acute myeloid leukemia aims to help patients live longer without their cance…
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…
VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patients
Can a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?
The VALIANT study, a phase 2 trial, evaluated the efficacy and safety of subcutaneous verekitug (UPB-101) versus placebo in adults with seve…
A new asthma injection aims to reduce dangerous flare-ups and improve breathing for adults with severe asthma in a completed trial.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Phase IIb trial of HH-003 injection for chronic HDV infection completes enrollment of 101 patients
Could a new antibody treatment help people with a serious liver infection?
A multicenter, randomized, controlled, open-label Phase IIb study assessed the efficacy and safety of HH-003 injection in subjects with chro…
A new antibody injection helped control a serious liver virus and heal inflammation in patients with chronic hepatitis delta infection.
Phase 1b/2 study of ERAS-007 combinations in advanced GI malignancies completes enrollment of 101 patients
Can a new drug combination help people with advanced colorectal or pancreatic cancer?
A Phase 1b/2 platform study evaluated ERAS-007 in combination with other cancer therapies in patients with advanced gastrointestinal maligna…
A new drug combination tested in advanced colorectal and pancreatic cancer aims to find safe doses and early signs of tumor shrinkage in pat…
Phase 2 trial tests metformin with neoadjuvant radiochemotherapy for locally advanced rectal cancer
Could a common diabetes drug help people with rectal cancer respond better to treatment?
A Phase 2 trial (n=60) evaluated adding metformin to neoadjuvant radiochemotherapy (capecitabine + 50 Gy radiation) for locally advanced rec…
Adding a common diabetes pill to pre-surgery treatment for rectal cancer may help clear out cancer cells before the operation begins.
LSD Microdosing Shows Mood Improvement in Major Depressive Disorder: Phase 2a Trial
Can microdosing LSD really boost mood in people with depression?
An open-label trial of microdosed LSD in major depressive disorder showed mood improvements on dosing days (p = 0.009 to 0.039) but no chang…
People with depression taking microdosed LSD for eight weeks reported feeling happier and more creative on dosing days while symptoms droppe…
Phase II Study on SHR-8068 Injection in Colorectal Cancer Now Recruiting
Could a new treatment help fight colorectal cancer more effectively?
A Phase II trial is recruiting to assess SHR-8068 with Adebrelimab and Bevacizumab in colorectal cancer for pCR and PFS.
A new drug combo for colorectal cancer is being tested in 200 patients to see if it improves survival and tumor response.
Phase 2 Trial: SHR-1701 Plus Chemoradiotherapy for Advanced Rectal Cancer
Could a new drug boost treatment for severe colorectal cancer?
A Phase 2 trial is recruiting to evaluate SHR-1701 with chemoradiotherapy in severe CRC. Primary outcome is pCR.
A new drug combined with standard chemo and radiation aims to clear severe colorectal cancer before surgery in an upcoming trial.
Phase 2b Study Evaluates KT-621 for Eosinophilic Asthma
Can KT-621 help people with severe asthma breathe easier?
A Phase 2b trial is assessing KT-621's efficacy and safety in 264 adults with moderate to severe eosinophilic asthma.
A new drug called KT-621 is being tested to help people with uncontrolled moderate to severe eosinophilic asthma breathe easier by improving…
Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe Asthma
Could a new drug help people with severe asthma breathe easier?
A Phase 2 trial is assessing the safety and efficacy of brenipatide versus placebo in 531 participants with moderate-to-severe asthma. The p…
A new asthma drug trial aims to reduce flare-ups and improve breathing for adults with moderate-to-severe asthma over the next year.
Study Validates Genotype Predictor of TIPN in African American Breast Cancer Patients
Could your genes predict nerve pain from breast cancer treatment?
This phase II trial with 249 participants evaluates a germline predictor of taxane-induced peripheral neuropathy (TIPN) in African American …
A genetic marker may predict severe nerve pain from breast cancer chemo in African American patients, with docetaxel possibly causing fewer …
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients
Could a new biomarker improve kidney transplant outcomes for patients?
A Phase 2 study is recruiting 800 kidney transplant recipients to assess HLA-DR/DQ mMM scores as prognostic biomarkers. A nested RCT will ev…
A new kidney transplant biomarker could predict complications, while a follow-up trial tests if switching to abatacept improves function and…
Phase 2 Trial: Cytisine and ASA for Inflammation in Lifelong Smokers
Can quitting smoking and changing your diet really reduce lung inflammation?
A Phase 2 trial evaluates cytisine for smoking cessation and ASA for inflammation in 2000 lifelong smokers.
Quitting smoking, eating better, and moving more can reduce lung inflammation in lifelong smokers, offering a path to breathe easier and low…
Phase II Trial Explores Serplulimab and Chemoradiotherapy for GEJ Adenocarcinoma
Can a new treatment approach improve outcomes for patients with advanced stomach cancer?
A phase II trial investigates serplulimab with mSOX and radiotherapy in 48 patients with cStage III GEJ adenocarcinoma.
A new trial combines immunotherapy, chemotherapy, and radiation to clear advanced stomach cancer before surgery, aiming for no surviving cel…
Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
Could Targeted Radiation Therapy Offer Hope for Lung Cancer Patients?
This Phase 2 trial evaluates the addition of liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy in metastatic NSCLC.…
A new trial tests if adding targeted liver radiation to standard drugs helps metastatic lung cancer patients live longer without disease pro…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
Could a New Drug Offer Hope for Kidney Disease Sufferers?
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pe…
A new drug called ManNAc may help reduce protein loss in urine for people with kidney scarring, offering hope for those facing dialysis or t…
Phase 2 Trial Evaluates mRNA Influenza Vaccines' Safety and Immunogenicity in Adults
Could This New Vaccine Help Us Finally Beat the Flu?
This Phase 2 trial investigates the safety and immunogenicity of five mRNA-based influenza vaccines in 770 healthy adults. Primary outcomes …
Pfizer is testing new mRNA flu vaccines in healthy adults to see if they trigger a stronger immune response and reduce flu complications bet…
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty
Can a New Drug Combination Help Older Adults with HIV Regain Strength?
Phase II trial of dasatinib and quercetin (D+Q) in 82 HIV+ frail/prefrail adults shows potential in improving gait speed. Primary endpoint: …
A new trial tests if two drugs help older adults with HIV regain strength and walk better after years of frailty.
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
Could a Simple Test Help Tailor Breast Cancer Treatment?
Phase II study shows RAD51-foci score predicts olaparib response in BRCA1/2, PALB2, RAD51C/D mutated breast cancer. Study enrolled 65 patien…
A new test may help doctors choose the right drug sooner for women with advanced breast cancer who have specific genetic mutations.
Phase 1/2 Study of Dual-Target CAR-NK Cells in Recurrent Ovarian Cancer
Could New Cell Therapy Change the Game for Women with Recurrent Ovarian Cancer?
This Phase 1/2 trial assesses the safety and preliminary efficacy of dual-target CAR-NK cells in recurrent ovarian cancer, focusing on dose-…
Women with recurrent ovarian cancer may find new hope in a trial testing dual-target CAR-NK cells designed to attack tumors that resist stan…
Phase 2 Study of BGB-16673 in B-Cell Malignancies: Safety and Dose Findings
Could This New Drug Offer Hope for Patients with Tough Blood Cancers?
This ongoing Phase 1/2 trial evaluates BGB-16673 in B-cell malignancies, focusing on safety and dose determination. Primary outcomes include…
Patients with tough B-cell blood cancers may find a new option in the drug BGB-16673, currently being tested to find the right safe dose and…
Phase II Trial: HST-NEETs Shows Promise in HIV-Associated Lymphoma Post-ASCT
Can a New Treatment Help Patients with HIV-Related Lymphoma Beat the Odds?
In a Phase II trial, HST-NEETs were administered post-ASCT in 12 patients with HIV-associated lymphoma. The study aimed to assess the feasib…
A new treatment combining immune therapy and bone marrow transplant aims to help patients with HIV-related lymphoma receive care sooner afte…
Phase II Trial Explores Nivolumab in High-Risk HIV-Associated Anal Cancer
Can New Treatments Help Fight HIV-Related Anal Cancer More Effectively?
This Phase II trial investigates the safety of reduced intensity CRT in low-risk HIV-associated anal cancer and nivolumab post-CRT in high-r…
A new trial tests gentler radiation and chemotherapy for low-risk HIV anal cancer, while adding immunotherapy for high-risk cases to improve…
Phase 2 Trial of Icalcaprant for MDD: Assessing Efficacy and Safety
Could This New Drug Help Ease Severe Depression Symptoms?
A Phase 2 trial is evaluating the efficacy and safety of oral Icalcaprant in 195 adults with MDD. Primary outcomes include changes in MADRS …
A new drug called Icalcaprant is being tested to see if it can help adults with major depressive disorder who are currently experiencing a m…